Cryo Cell International (CCEL) Net Income towards Common Stockholders (2010 - 2026)

Cryo Cell International has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting $47108.0 for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 83.35% year-over-year to $47108.0; the TTM figure through Feb 2026 stood at -$2.7 million (down 2170.66% YoY), while the FY2025 annual figure was -$2.4 million, down 704.18% from the prior year.
• Net Income towards Common Stockholders rose to $47108.0 in Q1 2026, from -$3.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for CCEL reached as high as $1.1 million in Q3 2024 and fell as low as -$11.2 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is $556241.0 (2024), against an average of -$513555.5.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 1435.61% — and 2024, when it jumped 196.77%.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $837822.0 in 2022, then tumbled by 1435.61% to -$11.2 million in 2023, then soared by 83.36% to -$1.9 million in 2024, then slumped by 105.06% to -$3.8 million in 2025, then jumped by 101.23% to $47108.0 in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $47108.0, -$3.8 million, and $749408.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.